Aims-To investigate the immunohistochemical expression of bcl-2 and p53 proteins in nasopharyngeal carcinomas in relation to the expression of the Epstein-Barr virus (EBV) encoded EBER messenger RNAs (mRNAs) and latent membrane protein-i (LMP-1). Methods-Formalin fixed, paraffin wax embedded tissue from 44 nasopharyngeal carcinomas (NPCs) was stained by immunohistochemistry for p53, bcl-2 and LMP-1 proteins and by RNA in situ hybridisation for EBER mRNAs.
The bcl-2 oncogene has been detected as a transcriptionally active unit on chromosome 18 in the vicinity ofthe breakpoint of translocation t(l 4;1 8) carrying follicular lymphomas. 3 The translocation leads to unregulated elevated expression of an otherwise unchanged bcl-2 protein. 4 This protein functions in an antioxidant pathway to prevent programmed cell death (apoptosis) and is localised to intracellular sites of oxygen free radical generation, including mitochondria, endoplasmic reticula and the nuclear membrane.' Using immunohistochemistry, bcl-2 protein has been detected in B and T non-Hodgkin's lymphomas lacking the t(l 4; 18) translocation. 6 In addition, bcl-2 protein has been detected in epithelial malignancies and is reported to have prognostic value.79
P53 is thought to act as a tumour suppressor gene and is located on the short arm of chromosome 17 . It encodes a 53 kilodalton phosphoprotein which is involved in the negative regulation of cellular growth by controlling entry of the cell into S phase. ' 
